



NLCA key recommendations for the next round of audit

Reviewed January 2017

DATA COMPLETENESS	STANDARD
Case ascertainment	95%
Valid performance status (PS) and stage	≥ 90%
Patients with stage I-II and PS 0-1, completeness for FEV1 and FEV1%	> 75%
PROCESS	
Proportion of patients seen by lung CNS	≥ 90%
Proportion of patients where lung CNS present for diagnosis	≥ 80%
Proportion of patients with pathological confirmation of lung cancer	≥ 80%
Proportion of patients where the pathology code is NSCLC-NOS	< 15%
Proportion of patients receiving PET-CT scan before surgery or radical radiotherapy	≥ 90%
Proportion of patients receiving chemotherapy for SCLC starting treatment within 2 weeks of pathological diagnosis	≥ 80%
TREATMENT & OUTCOME	
The casemix-adjusted odds ratio will be used to determine outlier status, but organisations can use the 2015 mean results (shown below) as a guide to performance	
	2015 mean
Active anticancer treatment rates for patients	60%
Surgical resection rates for NSCLC patients	17%
Radical treatment rates for patients with stage I/II NSCLC	70%
Chemotherapy rates for SCLC	≥ 69%
Systemic anticancer treatment rates for PS (0-1) stage IIIB/IV NSCLC	64%
1 year survival	38%

Glossary

CNS: clinical nurse specialist

FEV1: forced expiratory volume in 1 second

NSCLC: non-small cell lung cancer

NOS: not otherwise specified

PET - CT: positron emission tomography – computed tomography

SCLC: small cell lung cancer

PS: performance status

For more information contact NLCA@rcplondon.ac.uk